Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark.
Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet & Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark
J Nucl Med. 2015 Dec;56(12):1895-900. doi: 10.2967/jnumed.115.161216. Epub 2015 Oct 1.
The somatostatin receptor subtype 2 is expressed on macrophages, an abundant cell type in the atherosclerotic plaque. Visualization of somatostatin receptor subtype 2, for oncologic purposes, is frequently made using the DOTA-derived somatostatin analogs DOTATOC or DOTATATE for PET. We aimed to compare the uptake of the PET tracers (68)Ga-DOTATOC and (64)Cu-DOTATATE in large arteries, in the assessment of atherosclerosis by noninvasive imaging technique, combining PET and CT. Further, the correlation of uptake and cardiovascular risk factors was investigated.
Sixty consecutive patients with neuroendocrine tumors underwent both (68)Ga-DOTATOC and (64)Cu-DOTATATE PET/CT scans, in random order. For each scan, the maximum and mean standardized uptake values (SUVs) were calculated in 5 arterial segments. In addition, the blood-pool-corrected target-to-background ratio was calculated. Uptake of the tracers was correlated with cardiovascular risk factors collected from medical records.
We found detectable uptake of both tracers in all arterial segments studied. Uptake of (64)Cu-DOTATATE was significantly higher than (68)Ga-DOTATOC in the vascular regions both when calculated as maximum and mean uptake. There was a significant association between Framingham risk score and the overall maximum uptake of (64)Cu-DOTATATE using SUV (r = 0.4; P = 0.004) as well as target-to-background ratio (r = 0.3; P = 0.04), whereas no association was found with (68)Ga-DOTATOC. The association of risk factors and maximum SUV of (64)Cu-DOTATATE was found driven by body mass index, smoking, diabetes, and coronary calcium score (P < 0.001, P = 0.01, P = 0.005, and P = 0.03, respectively).
In a series of oncologic patients, vascular uptake of (68)Ga-DOTATOC and (64)Cu-DOTATATE was found, with highest uptake of the latter. Uptake of (64)Cu-DOTATATE, but not of (68)Ga-DOTATOC, was correlated with cardiovascular risk factors, suggesting a potential role for (64)Cu-DOTATATE in the assessment of atherosclerosis.
比较正电子发射断层扫描（PET）示踪剂（68）Ga-DOTATOC 和（64）Cu-DOTATATE 在大动脉中的摄取情况，评估将 PET 与 CT 相结合的非侵入性成像技术在动脉粥样硬化中的应用。此外，还研究了摄取与心血管危险因素的相关性。
连续 60 例神经内分泌肿瘤患者分别行（68）Ga-DOTATOC 和（64）Cu-DOTATATE PET/CT 扫描，顺序随机。对于每种扫描，计算 5 个动脉段的最大标准化摄取值（SUVmax）和平均标准化摄取值（SUVmean）。此外，还计算了血池校正后的靶/背景比。示踪剂的摄取与从病历中收集的心血管危险因素相关。
我们发现，在所研究的所有动脉段中，均能检测到两种示踪剂的摄取。（64）Cu-DOTATATE 的摄取均显著高于（68）Ga-DOTATOC，无论是最大摄取值还是平均摄取值。Framingham 风险评分与（64）Cu-DOTATATE 的总最大摄取量之间存在显著相关性，使用 SUV（r = 0.4；P = 0.004）和靶/背景比（r = 0.3；P = 0.04）。然而，与（68）Ga-DOTATOC 之间没有相关性。（64）Cu-DOTATATE 的最大 SUV 与危险因素的相关性归因于体重指数、吸烟、糖尿病和冠状动脉钙评分（P < 0.001、P = 0.01、P = 0.005 和 P = 0.03）。
在一系列肿瘤患者中，发现（68）Ga-DOTATOC 和（64）Cu-DOTATATE 在大动脉中的摄取，后者摄取更高。（64）Cu-DOTATATE 的摄取与心血管危险因素相关，但（68）Ga-DOTATOC 的摄取则不相关，这表明（64）Cu-DOTATATE 可能在动脉粥样硬化的评估中发挥作用。
Zotero 插件